Chennai (Tamil Nadu) [India], May 4 (/PRNewswire): Annalise.ai, one of the world's largest artificial intelligence (AI) radiology compes, has today announced it is continuing its global expansion with the opening of the Annalise India Centre in Chennai Annalise's first establishment in India.
The expansion into India continues Annalise.ai's fast-paced growth trajectory as it continues to increase its visibility and capabilities in new markets like the USA, UK, Europe, and Asia. The Annalise India Centre will become a part of this international network and concentrate on the development and marketing of new products. Annalise.ai combines superior imaging data with the very best in computer science to produce comprehensive AI clinical decision support solutions, empowering clinicians to make accurate, faster decisions.
According to Lakshmi Gudapakkam, CEO of Annalise.ai - "It makes perfect sense for Annalise.ai to have a presence in what is rapidly developing as a prominent medical device region. India is one of the fastest growing medical device markets globally and represents a very exciting opportunity," He added, "This is also a chance to make use of the diverse talent pool that makes India a technological hub and accelerate development of new AI applications."
Annalise.ai currently plans to hire across product development including software engineers, product managers and regulatory, as well as to expand the commercial and business services teams.
The two flagship products in the Annalise product line are Annalise Enterprise CTB, one of the most complete AI decision support solutions available for non-contrast CT brain studies, and Annalise Enterprise CXR, one of the most comprehensive AI clinical decision-support solutions available for chest x-rays. These solutions are clinical assisting tools that employ deep learning algorithms to detect the possible existence of up to 124 chest x-ray results and up to 130 brain CT scan findings, including a wide spectrum of disorders that call for immediate intervention. The usage of Annalise.ai by radiologists as an assistance tool has been demonstrated to improve detection accuracy and gives clinicians access to a second pair of eyes. Annalise.ai has researched and deployed its AI technology across hundreds of leading hospitals and research clinics in Australia, the United Kingdom, the United States and Asia. These deployments have shown the improvement of diagnostic accuracy across patient populations in every country.
Dimitry Tran, Co-Founder of harrison.ai and board director of Annalise.ai said, "We are thrilled to announce that Annalise.ai will be opening its first local office in India to support the global growth ambitions of the company. Our goal is to redefine what's possible in radiology, to benefit millions of patients every day and we believe that the move into India will not only support our team to achieve this but also work with the Indian government's mission of providing equitable, affordable and quality diagnostic services for both communicable and non-communicable diseases."
While spending on AI in India is anticipated to reach USD 11.78 billion in 2025 and add $1 trillion to the country's economy by 2035, AI can offer more than just financial advantages. The World Economic Forum estimates that India has 64 doctors per 100,000 people, which has an influence on access to care, especially in rural areas. Access to care can be increased and made more egalitarian with AIenabled medical technology.
Annaise.ai, which debuted in Australia in 2021, has gained international recognition and witnessed rapid growth in a short period of time. Its quick global expansion shows how useful AI in healthcare can be and how it has the ability to address problems in different regional markets. Technology is a critical element of modern healthcare and has the potential to improve access to not only affordable but quality healthcare. Radiology is the first touchpoint in the patient journey and AI enabled diagnostic tools will improve diagnosis and accuracy, improving patient care and treatment.
Contact
Virginie Cosentino
virginiecosentino@slingstone.com
This story is provided by PRNewswire. will not be responsible in any way for the content of this article. (/PRNewswire)
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor